$1.59 Billion is the total value of Sofinnova Investments, Inc.'s 69 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KRTX | Karuna Therapeutics Inc | $233,538,484 | -22.0% | 1,381,149 | 0.0% | 14.73% | -24.9% | |
| NTRA | Natera Inc | $137,199,780 | -9.1% | 3,100,560 | 0.0% | 8.66% | -12.4% | |
| ASND | Ascendis Pharma A/Ssponsored adr | $70,607,556 | +4.9% | 754,032 | 0.0% | 4.45% | +1.0% | |
| AVTE | Aerovate Therapeutics Inc | $51,005,369 | -20.9% | 3,758,686 | 0.0% | 3.22% | -23.8% | |
| VERA | Vera Therapeutics Inccl a | $47,534,709 | -14.6% | 3,467,156 | 0.0% | 3.00% | -17.7% | |
| YMAB | Y-mAbs Therapeutics Inc | $11,958,815 | -19.7% | 2,194,278 | 0.0% | 0.75% | -22.7% | |
| NXTC | Nextcure Inc | $3,446,694 | -28.3% | 2,671,856 | 0.0% | 0.22% | -31.1% | |
| NCNA | Nucana PLCsponsored adr | $3,415,999 | -22.8% | 5,599,999 | 0.0% | 0.22% | -25.9% | |
| BOLT | Bolt Biotherapeutics Inc | $2,864,614 | -18.8% | 2,754,437 | 0.0% | 0.18% | -21.6% | |
| Nucana PLC | $1,464,000 | -22.8% | 2,400,000 | 0.0% | 0.09% | -25.8% | ||
| PDSB | PDS Biotechnology Corp | $720,307 | +0.4% | 142,635 | 0.0% | 0.04% | -4.3% | |
| GRTX | Galera Therapeutics Inc | $539,958 | -94.4% | 3,083,712 | 0.0% | 0.03% | -94.6% | |
| FUSN | Fusion Pharmaceuticals Inc | $304,457 | -44.3% | 117,099 | 0.0% | 0.02% | -47.2% | |
| MIRM | Mirum Pharmaceuticals Inc | $287,212 | +22.1% | 9,089 | 0.0% | 0.02% | +20.0% | |
| SPRB | Spruce Biosciences Inc | $131,146 | +5.1% | 58,029 | 0.0% | 0.01% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.